September 23, 2025 a 12:38 pm
PFE: Analysts Ratings - Pfizer Inc.
Pfizer Inc. remains a major player in the biopharmaceutical industry, offering a wide range of medicines and vaccines globally. Despite its vast portfolio and numerous collaborations, the recent analyst ratings reflect a mixed sentiment, hinting at a cautious outlook. The company's performance in the coming quarters will be crucial in shaping investor sentiment.
Historical Stock Grades
The most recent analyst ratings for Pfizer Inc., as of September 2025, show a dominance of Hold recommendations, indicating a neutral stance by many analysts. The scores represent a cautious outlook as follows:
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 7 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over the past months, there has been a noticeable shift towards more conservative ratings, with a marked increase in Hold recommendations. This highlights a hesitation among analysts, possibly due to market uncertainties:
- A steady increase in Hold ratings, from 9 in early 2023 to 15 by September 2025.
- A decrease in Strong Buy recommendations, showing reduced confidence in robust upward potential.
- The overall sentiment shows stability but with a cautious tilt as economic and market conditions remain volatile.
Percentage Trends
Analyzing the percentage distribution of analyst ratings reveals shifting opinions. Notably, there is a decline in aggressive buying sentiment, with an increasingly conservative approach:
- The percentage of analysts recommending Strong Buy dropped from 12% in mid-2024 to 3% by late 2025.
- Hold ratings surged, accounting for 63% of all recommendations in September 2025, up from 38% in 2023.
- This reflects a growing consensus that Pfizer's growth prospects are steady but not extraordinary, warranting a more neutral stance.
Latest Analyst Recommendations
The latest analyst recommendations suggest a maintenance of current views, with no significant upgrades or downgrades. This indicates stability but no strong impetus for bullishness:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-06 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-08-06 | Neutral | Neutral | B of A Securities |
| 2025-08-06 | Neutral | Neutral | Citigroup |
| 2025-04-30 | Neutral | Neutral | UBS |
| 2025-04-08 | Neutral | Neutral | UBS |
Analyst Recommendations with Change of Opinion
While recent recommendations largely maintain previous views, there have been some downgrades and upgrades, reflecting evolving sentiments about Pfizer's performance:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-08-08 | Outperform | Neutral | Daiwa Capital |
| 2024-03-22 | Hold | Buy | Argus Research |
| 2024-01-04 | Market Perform | Outperform | TD Cowen |
| 2023-10-16 | Buy | Hold | Jefferies |
Interpretation
The recent analyst sentiment towards Pfizer Inc. reflects a stable yet cautious outlook. Despite the company's solid market position, the increased Hold ratings indicate analysts are awaiting clearer growth signals before adjusting their recommendations. The prevalence of Neutral stances suggests a lack of significant short-term catalysts, but potential for a turnaround remains if strategic initiatives show success.
Conclusion
Pfizer Inc. stands at a crossroads where its historic strength in the pharmaceutical industry meets recent market skepticism. The balance of ratings points to a cautious confidence, underlined by stability in existing analyst recommendations. Potential risks include challenges in expanding growth pathways and navigating regulatory hurdles, while opportunities persist in product innovation and strategic partnerships. As the data shows, a patient, observant approach might serve current and prospective investors well at this juncture.